DPE Deutsche Private Equity and a fund advised by Maxburg Capital Partners sold their stake in PharmaZell to international private equity group Bridgepoint. EGO HUMRICH WYEN again acted as legal advisor to MAXBURG on this transaction.
PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs, and enjoys leading industry positions in several products that treat respiratory, inflammatory and liver diseases driven by changing lifestyle habits. Many of the Company's products require special handling procedures and/or technologies. Headquartered in Raubling (near Munich), PharmaZell operates four state-of-the-art production and R&D sites in Germany, Italy and India with over 900 employees globally.
Maxburg Capital Partners is an investment management company focusing on the German-speaking markets. The funds advised by Maxburg Capital Partners concentrate on long-term investments in profitable, medium-sized companies with the goal of enduring and sustainable value appreciation.